REMARKS

Claims 30-49 are pending in the instant application.

Applicants have canceled original claims 1-29. Applicants have

added new claims 30-49. Claims 30 and 34 are independent. The

new claims find support in the original claims, mainly for claims

5 and 16. Applicants have not raised any issue of new matter.

Conclusion

Applicants assert that the present application is in

condition for allowance.

If the Examiner believes for any reason that personal

communication will expedite prosecution of this application, the

Examiner is invited to telephone the undersigned at (302) 934-

4395, in Millsboro, Delaware.

If necessary, the Commissioner is hereby authorized in this,

concurrent, and further replies, to charge payment or credit any

overpayment to Deposit Account No. 02-2334 for any additional

7

Attorney Docket: I-2002.015 US

fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly extension of time fees.

Respectfully submitted,

Mark W. Milstead

Registration No. 45,825

Attorney Docket NO.: I/2002.015 US

Akzo Nobel
Pharma Patent Department
PO Box 318
29160 Intervet Lane
Millsboro, DE 19966-0318
Tel: (302) 934-4395

Fax: (302) 934-4395

MWM

Attorney Docket: I-2002.015 US

Customer No.: 31846 Express Mail: EV561841229 US